Pre-Made Efmitermant Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Efmitermant Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efmitermant Alfa is a human follistatin fragment fused via a peptidyl linker to a human immunoglobulin G2 Fc fragment, dimer: it is used for the treatment of Charcot-Marie-Tooth disease
| Products Name (INN Index) | Pre-Made Efmitermant Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP |
|---|---|
| INN Name | efmitermant alfa |
| Target | MSTN |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [FST (follistatin)]2 – IGHG2 Fc (Fragment constant) |
| VD LC | Fusion – [FST (follistatin)]2 – IGHG2 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Acceleron?Pharma, Inc (Cambridge UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MSTN |
| Package |
